Skip to main content
logo
Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.1900
-0.0050 (-2.56%)
At close: Oct 9, 2026

Lyra Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
051427510057
Market Cap Growth
-97.34%-59.54%-95.09%175.61%76.26%-61.52%
Enterprise Value
1515-3179-90
Last Close Price
0.193.0810.32262.00157.00218.00

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.8513.748.81176.7973.32198.95
PB Ratio
-0.03-0.511.173.081.241.65
P/TBV Ratio
--1.173.081.241.65

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
36.9437.16-115.00-0.97

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
-2.82-2.822.970.300.030.04
Net Debt / Equity Ratio
-1.34-1.34-0.53-0.85-1.18-1.29
Net Debt / EBITDA Ratio
-0.49-0.490.101.161.771.04
Net Debt / FCF Ratio
-0.50-0.500.091.182.201.52
Asset Turnover
0.010.010.020.010.020.00
Quick Ratio
1.671.673.215.246.772.51
Current Ratio
1.711.713.415.356.972.63
Return on Equity (ROE)
-6594.98%-6594.98%-184.99%-73.67%-96.08%-79.98%
Return on Assets (ROA)
-36.06%-36.06%-36.33%-32.43%-41.70%-40.18%
Return on Capital Employed (ROCE)
-111.20%-111.20%-113.10%-53.30%-57.60%-119.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-8575.50%-529.01%-691.58%-22.76%-55.31%-76.74%
FCF Yield
-8592.11%-530.03%-535.50%-23.36%-43.58%-51.51%
Buyback Yield / Dilution
-19.29%-19.29%-30.74%-64.72%-132.83%-51.17%